In the future, you don’t need to be prescribed to buy this medicine in the future

Recently, the State Drug Administration issued an announcement that the potassium sulfate potassium glucose tablets were converted from prescription drugs to over -the -counter drugs. This means that in the future, patients do not need to be prescribed by practicing physicians or practicing assistants, and they can judge, purchase and use the medicine by themselves. It should be noted that the newly released instructions show that the drug is an analgesic non -prescription drug, which is used for osteoarthritis (such as knee joints, hip joints, spine, shoulders, hands, wrist joints, and ankles joints Wait). Three types of people are disabled, including disability and patients with breastfeeding women, patients with allergies to sulfate glucose or any auxiliary materials in this product, and disabled patients with hyperkalemia patients.

It is understood that Article 2 of the "Administrative Measures for the Classification of Prescription Drugs and African Medicine (Trial)" stipulates that according to the different drugs, specifications, indications, dose, and administration channels, the drugs are managed according to prescription drugs and non -prescription drugs, respectively. The prescription medicine must be prepared, purchased and used by prescriptions for practicing physicians or practicing assistants; non -prescription drugs can judge, purchase and use it by themselves without the prescription of practicing physicians or practicing assistants. From prescription drugs to over -the -counter drugs, the number of channels for these medicines to patients in the hands of patients are more likely to be bought by patients. However, for the medication, there is no professional physician guidance, and only the instructions can be relying on the medication, so it is necessary to use it strictly in accordance with the reference manual to avoid adverse drug reactions.

In addition, the State Drug Administration announced simultaneously that the relevant drug listing license holders shall submit the amendments to the provincial drug supervision and administration department to record the amendments in accordance with the relevant provisions such as the "Administrative Measures for the Registration of Drug Registration" before April 6, 2023. The instructions revised the content to notify the relevant medical institutions, pharmaceutical business enterprises and other units in a timely manner. Other contents other than the content of the non -prescription drug instructions are implemented in the instructions beyond the content of the original approval document. If the drug label involves related content, it should be revised together. Drugs who are submitted from the date of filing of drug listing permits shall not continue to use the original drug instructions.

Wang Jiangli, a reporter from Xi'an Newspaper, Wang Jiangli

- END -